Search - tctmd.com

Displaying 481 - 500 of 739

Sort: Relevancy | Date

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

TCTMD’s Top 10 Most Popular Stories for October 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2018

October 31, 2018

Study Questions Role of BP Meds in Patients With Hypertension but No Other CVD Risk Factors

News Daily News

Study Questions Role of BP Meds in Patients With Hypertension but No Other CVD Risk Factors

October 30, 2018

Dabigatran Trials Come Up Short for Stroke of Unknown Cause and Cerebral Venous Thrombosis

News Daily News

Dabigatran Trials Come Up Short for Stroke of Unknown Cause and Cerebral Venous Thrombosis

October 26, 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

September 24, 2018

Aspirin Falters Yet Again in Primary Prevention: ASPREE

News Daily News

Aspirin Falters Yet Again in Primary Prevention: ASPREE

Michael O'Riordan

September 17, 2018

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

News Conference News ESC 2018

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

August 26, 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

August 26, 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

August 26, 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

Hospital Readmissions at 30 Days Declining for Stroke Patients

News Daily News

Hospital Readmissions at 30 Days Declining for Stroke Patients

Michael O'Riordan

August 20, 2018

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

August 15, 2018

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

News Daily News

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

August 13, 2018

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

News Daily News

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Michael O'Riordan

August 13, 2018

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

NOACs Particularly Beneficial for Women With A-fib, Study Suggests

News Daily News

NOACs Particularly Beneficial for Women With A-fib, Study Suggests

July 11, 2018

Bleeding Risk Increased With NSAID Use in Anticoagulated A-fib Patients: RE-LY Analysis

News Daily News

Bleeding Risk Increased With NSAID Use in Anticoagulated A-fib Patients: RE-LY Analysis

July 10, 2018

Real-world Analysis Suggests Apixaban Is Safest of the NOACs, Even for Patients With A-fib

News Daily News

Real-world Analysis Suggests Apixaban Is Safest of the NOACs, Even for Patients With A-fib

July 06, 2018

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.